Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.”In the company’s words, NCT05087056 on ClinicalTrials.gov
- Tested for
- Meningitis, Meningococcal
- Main trialPhase 2
- “The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.”In the company’s words, NCT05087056 on ClinicalTrials.gov
Other drugs for Meningitis, Meningococcal
- Group ACYW135 Meningococcal Conjugate VaccineSinovac Biotech Co., Ltd · Phase 3
- DTcP-Hib-MCV4CanSino Biologics Inc. · Phase 1
- ACYW135XSinovac Life Sciences Co., Ltd. · Phase 1
- Batch 1 ofCanSino Biologics Inc. · Marketed (Phase 4 trial)
- RMenBGSK · Marketed (Phase 4 trial)
Coming up1
- 10 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 10 Mar 2027 | Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents | |
| Phase 3Completed | 3 May 2023 | Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026